Abstract
Nonadherence to immunosuppressive regimens among solid organ transplantation to range has been estimated from 15% to 55%. This problem has been identified as a leading cause of preventable graft loss. Tacrolimus once daily Advagraf has been developed to provide a more convenient dosing regimen to improve adherence. The aim of this study was to analyze the safety of a 1:1 dose conversion from twice-daily tacrolimus (Prograf) to Advagraf in 36 stable liver transplant recipients. The tacrolimus whole blood trough level at T0 was 6.7 ± 2.9 ng/mL with a daily dose of 3.7 ± 1.8 mg. The mean tacrolimus blood trough levels at T1 (7 days) and T2 (14 days) were 5.8 ± 2.5 and 5.8 ± 1.8 ng/mL with mean daily doses of 3.9 ± 1.9 and 4.1 ± 1.8 mg, respectively. There was no significant difference between T0, T1, and T2, either for tacrolimus blood trough levels or for tacrolimus daily dosages. Liver and renal function tests remained stable; no episodes of acute rejection were encountered after the conversion. A switching policy using a dose ratio of 1:1 from twice-daily tacrolimus to once-daily prolonged-release tacrolimus was safely applied to stable liver transplant recipients.
| Original language | English |
|---|---|
| Pages (from-to) | 1320-1321 |
| Number of pages | 2 |
| Journal | Transplantation Proceedings |
| Volume | 42 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - May 2010 |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Transplantation
Cite this
Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients. / Comuzzi, C.; Lorenzin, D.; Rossetto, A.; Faraci, M. G.; Nicolini, D.; Garelli, P.; Bresadola, V.; Toniutto, P.; Soardo, G.; Baroni, G. S.; Adani, G. L.; Risaliti, A.; Baccarani, U.
In: Transplantation Proceedings, Vol. 42, No. 4, 05.2010, p. 1320-1321.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients
AU - Comuzzi, C.
AU - Lorenzin, D.
AU - Rossetto, A.
AU - Faraci, M. G.
AU - Nicolini, D.
AU - Garelli, P.
AU - Bresadola, V.
AU - Toniutto, P.
AU - Soardo, G.
AU - Baroni, G. S.
AU - Adani, G. L.
AU - Risaliti, A.
AU - Baccarani, U.
PY - 2010/5
Y1 - 2010/5
N2 - Nonadherence to immunosuppressive regimens among solid organ transplantation to range has been estimated from 15% to 55%. This problem has been identified as a leading cause of preventable graft loss. Tacrolimus once daily Advagraf has been developed to provide a more convenient dosing regimen to improve adherence. The aim of this study was to analyze the safety of a 1:1 dose conversion from twice-daily tacrolimus (Prograf) to Advagraf in 36 stable liver transplant recipients. The tacrolimus whole blood trough level at T0 was 6.7 ± 2.9 ng/mL with a daily dose of 3.7 ± 1.8 mg. The mean tacrolimus blood trough levels at T1 (7 days) and T2 (14 days) were 5.8 ± 2.5 and 5.8 ± 1.8 ng/mL with mean daily doses of 3.9 ± 1.9 and 4.1 ± 1.8 mg, respectively. There was no significant difference between T0, T1, and T2, either for tacrolimus blood trough levels or for tacrolimus daily dosages. Liver and renal function tests remained stable; no episodes of acute rejection were encountered after the conversion. A switching policy using a dose ratio of 1:1 from twice-daily tacrolimus to once-daily prolonged-release tacrolimus was safely applied to stable liver transplant recipients.
AB - Nonadherence to immunosuppressive regimens among solid organ transplantation to range has been estimated from 15% to 55%. This problem has been identified as a leading cause of preventable graft loss. Tacrolimus once daily Advagraf has been developed to provide a more convenient dosing regimen to improve adherence. The aim of this study was to analyze the safety of a 1:1 dose conversion from twice-daily tacrolimus (Prograf) to Advagraf in 36 stable liver transplant recipients. The tacrolimus whole blood trough level at T0 was 6.7 ± 2.9 ng/mL with a daily dose of 3.7 ± 1.8 mg. The mean tacrolimus blood trough levels at T1 (7 days) and T2 (14 days) were 5.8 ± 2.5 and 5.8 ± 1.8 ng/mL with mean daily doses of 3.9 ± 1.9 and 4.1 ± 1.8 mg, respectively. There was no significant difference between T0, T1, and T2, either for tacrolimus blood trough levels or for tacrolimus daily dosages. Liver and renal function tests remained stable; no episodes of acute rejection were encountered after the conversion. A switching policy using a dose ratio of 1:1 from twice-daily tacrolimus to once-daily prolonged-release tacrolimus was safely applied to stable liver transplant recipients.
UR - http://www.scopus.com/inward/record.url?scp=77952560702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952560702&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2010.03.106
DO - 10.1016/j.transproceed.2010.03.106
M3 - Article
C2 - 20534291
AN - SCOPUS:77952560702
VL - 42
SP - 1320
EP - 1321
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 4
ER -